Moffitt Cancer Center | Strategic Alliance Partners

Michael Shafique, MD, discusses treatment considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Andreas Saltos, MD, discusses the importance of broad molecular testing in non–small cell lung cancer.

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

HEPZATO KIT has demonstrated statistically significant benefit compared to best alternative care in patients with liver-dominant metastatic ocular melanoma, according to preliminary results from the phase 3 FOCUS trial.

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

Jing-Yi Chern, MD, ScM, discusses the role of maintenance PARP inhibition in patients with recurrent platinum-sensitive ovarian cancer, as well as remaining questions regarding the utility of PARP inhibitors in this setting.

Robert Wenham, MD, MS, FACOG, FACS, discusses the basis for combining chemotherapy, PARP inhibitors, and VEGF inhibitors with immunotherapy in ovarian cancer and ongoing research with ADCs in the field.

Robert Wenham, MD, MS, FACOG, FACS, discusses novel immunotherapy combinations for the treatment of patients with ovarian cancer.

Jing-Yi Chern, MD, ScM, discusses efforts being made to combine PARP inhibitors with chemotherapy and immunotherapy in patients with recurrent ovarian cancer.

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.

Two novel treatments options may shake up the landscape for treating patients with myelodysplasia syndrome.

Kendra Sweet, MD, discusses key findings from the OPTIC trial with ponatinib in chronic myeloid leukemia.

Kendra Sweet, MD, discusses treatment selection with TKIs in chronic myeloid leukemia.

Marilyn M. Bui, MD, PhD, highlights the importance of pathology in sarcoma and how it is the cornerstone of precision medicine.

In an interview with OncLive® Michael Shafique, MD, discusses examples of this groundbreaking research of immunotherapy combinations in NSCLC.

Anna Giuliano, PhD, discusses the work efforts to advance the reach of preventive vaccines and cancers, and the challenges researchers are facing in the process.

The addition of the experimental small molecule eprenetapopt to a standard treatment for myelodysplastic syndromes is showing promise in patients with TP53 mutations.

Christine Sam, MD, discusses the importance of ​performing geriatric assessments during the coronavirus disease 2019 pandemic​.

Richard D. Kim, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

Heather ​S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.

Rutika J. Mehta, MD, MPH, discusses the ​current treatment paradigm in HER2-positive gastric cancer. 

Kamran A. Ahmed, MD, discusses the impact of neratinib on patients with central nervous system metastases and HER2-positive breast cancer.

Jonathan Strosberg, MD, highlights key trials spanning gastrointestinal cancers, challenges faced in certain diseases, and the focus of future research efforts.

Hatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.

Heather ​S. Han, MD, discusses the importance of risk stratification in HER2-positive breast cancer.

Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.

Richard D. Kim, MD, discusses the evolving treatment landscape of HCC, the approval of atezolizumab/bevacizumab, and other pivotal data in HCC.

Christine Sam, MD, discusses strategies to mitigate the risk of the coronavirus disease 2019 in elderly patients with cancer.

Dae Won Kim, MD, discusses the NAPOLI-1 and NAPOLI-3 trials in metastatic pancreatic cancer, as well as the role of PARP inhibitors and remaining challenges in the space.

Richard D. Kim, MD, discusses the evolving treatment landscape of advanced hepatocellular carcinoma.